Editas Medicine, Inc.: management transactions · United States · SEC (Form 4)

About Editas Medicine, Inc.

Editas Medicine, Inc. is a U.S.-based biotechnology company listed on the NASDAQ in the United States. Headquartered in Cambridge, Massachusetts, with an operational site in Boulder, Colorado, the company is positioned in the highly innovative and highly volatile gene-editing segment. Founded in 2013 under the original name Gengine, Inc., it later adopted the Editas Medicine name that same year. The company’s identity is closely tied to CRISPR science, with a focus on translating CRISPR/Cas9 and CRISPR/Cas12a genome-editing systems into therapeutic programs. ([editasmedicine.com](https://www.editasmedicine.com/about/?utm_source=openai)) Editas is still best described as a clinical-stage, pre-commercial biotech rather than a revenue-generating pharmaceutical business. Its value proposition depends on scientific execution, regulatory milestones, and eventual commercialization, not on current product sales. The company’s pipeline is centered on transformative medicines for serious diseases with limited treatment options. Its lead in vivo candidate is EDIT-401, designed to treat hyperlipidemia, while EDIT-301 is an ex vivo gene-editing program being developed for hematologic diseases such as sickle cell disease. In earlier phases of the company’s development, Editas also advanced EDIT-101 in ophthalmology, underscoring the breadth of its platform approach. ([editasmedicine.com](https://www.editasmedicine.com/about/?utm_source=openai)) From a competitive standpoint, Editas operates in a field characterized by intense R&D competition, high technical barriers, and substantial clinical and regulatory risk. Its differentiation rests on deep CRISPR expertise and an increasing strategic emphasis on in vivo gene editing. Management has highlighted encouraging preclinical evidence for EDIT-401, including strong LDL-C reduction in non-human primates, which supports the program’s potential as a first-in-class or best-in-class contender in a large cardiometabolic market. ([ir.editasmedicine.com](https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-first-quarter-2026-results-and?utm_source=openai)) Recent developments have been important. In the first quarter of 2026, Editas said it remained on track to file an IND or CTA for EDIT-401 by mid-2026 and expects initial in-human proof-of-concept data by year-end 2026. The company also presented new preclinical EDIT-401 data at scientific meetings in spring 2026. In addition, Editas reported a favorable procedural development in its CRISPR patent dispute, with the U.S. Patent and Trademark Office reaffirming a prior Broad Institute victory in the interference proceeding involving CRISPR/Cas9 rights. For investors, Editas is therefore a speculative biotechnology name with meaningful upside optionality, but one that remains dependent on clinical progress, regulatory execution, and intellectual-property outcomes. ([ir.editasmedicine.com](https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-first-quarter-2026-results-and?utm_source=openai))